No connection

Search Results

KPTI vs SNWV

KPTI
Karyopharm Therapeutics Inc.
BEARISH
Price
$8.00
Market Cap
$180.3M
Sector
Healthcare
AI Confidence
90%
SNWV
SANUWAVE Health, Inc.
BEARISH
Price
$20.61
Market Cap
$177.1M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
KPTI
--
SNWV
50.27
Forward P/E
KPTI
-1.83
SNWV
-2061.0
P/B Ratio
KPTI
-0.5
SNWV
109.63
P/S Ratio
KPTI
1.23
SNWV
4.02
EV/EBITDA
KPTI
-4.3
SNWV
25.13

Profitability

Gross Margin
KPTI
9.93%
SNWV
77.11%
Operating Margin
KPTI
-52.36%
SNWV
16.66%
Profit Margin
KPTI
-134.21%
SNWV
26.82%
ROE
KPTI
--
SNWV
--
ROA
KPTI
-41.56%
SNWV
12.07%

Growth

Revenue Growth
KPTI
11.6%
SNWV
26.8%
Earnings Growth
KPTI
--
SNWV
--

Financial Health

Debt/Equity
KPTI
--
SNWV
14.19
Current Ratio
KPTI
1.12
SNWV
1.38
Quick Ratio
KPTI
0.98
SNWV
0.97

Dividends

Dividend Yield
KPTI
--
SNWV
--
Payout Ratio
KPTI
0.0%
SNWV
0.0%

AI Verdict

KPTI BEARISH

KPTI exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.50, indicating negative shareholder equity. While the stock has seen a speculative 1-year price surge of 100.5%, the underlying fundamentals are catastrophic with a profit margin of -134.21% and a consistent track record of missing earnings estimates (0/4 in the last year). Despite bullish analyst targets, the combination of insider selling and extreme operational inefficiency suggests a high risk of further capital erosion.

Strengths
Positive year-over-year revenue growth of 11.60%
Recent 1-year price recovery (+100.5%)
Improving EPS growth trend (+38.1% YoY), though still deeply negative
Risks
Negative Book Value (P/B -0.50) indicating insolvency risk
Extreme operational losses (Profit Margin -134.21%)
Critical Piotroski F-Score (1/9) signaling fundamental weakness
SNWV BEARISH

SNWV exhibits severe fundamental weakness, highlighted by a weak Piotroski F-Score of 3/9 and an extreme valuation gap. The stock is trading at $20.61, which is astronomically higher than its Graham Number ($1.32) and Intrinsic Value ($2.87). While revenue growth is strong at 26.8%, the company is burdened by a dangerous Debt/Equity ratio of 14.19 and a Price/Book ratio of 109.63. Despite 'strong buy' analyst ratings, the combination of bearish insider selling and a negative forward P/E suggests a high risk of a significant correction.

Strengths
Strong gross margins of 77.11%
Consistent revenue growth (26.8% YoY and Q/Q)
Positive current profit margin of 26.82%
Risks
Extreme overvaluation with a Price/Book ratio of 109.63
Critical leverage levels with a Debt/Equity ratio of 14.19
Weak financial health indicated by a Piotroski F-Score of 3/9

Compare Another Pair

KPTI vs SNWV: Head-to-Head Comparison

This page compares Karyopharm Therapeutics Inc. (KPTI) and SANUWAVE Health, Inc. (SNWV) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile